Select Page

Press Release

The US National Institutes of Health Awards Grant to Celsense, Inc. to Fund Novel Product Development

July 1, 2018 – Pittsburgh, Pennsylvania

The National Institute for Biomedical Imaging and Bioengineering (NIBIB), a branch of the US National Institutes of Health and the National Center for Advancing Translational Sciences (NCATS), have awarded a 6-month grant to fund research into the clinical translation of a novel MRI cell tracking composition. The composition was invented by Drs. Eric T. Ahrens, Roger Y. Tsien, and Alexander A. Kislukin. The composition was described in a peer-reviewed journal article in the Nature Materials in March 2016.

The Principal Investigator for this research project is Charles F. O’Hanlon, the CEO of Celsense, Inc. The project funded by this grant involves the translation of technology developed in the academic laboratory to a commercial enterprise to further develop the technology into a salable product. This will involve experimental work related to product formulation, manufacturing scale-up, supply chain development, and validating test methods for product release and quality control.

The new composition offers an opportunity to reduce the time required to acquire the fluorine image when it is used as a tracer agent in cell therapy. If the project is successful, the new composition may represent an improvement over existing fluorine MRI cell tracking technology.

“We are excited about this opportunity to work with Drs. Ahrens on this project. This new composition could represent an important breakthrough in this field, making the technology applicable to cell therapy development in additional disease states,” said Charlie O’Hanlon, President and CEO of Celsense, Inc.

About Celsense
Celsense, Inc. develops and offers a novel product that enables the non-invasive imaging of cells in vivo using magnetic resonance imaging (MRI). The company’s lead product Cell Sense CS-1000 is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense CS-1000 is the subject of a Drug Master File at US FDA and Health Canada and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870

Continue Exploring



Real-Time Results,<br />Faster and More Accurate

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

Send Us A Message

12 + 7 =

© 2020 Celsense, Inc. All rights reserved.